Shionogi and AnGes MG start phase I of NF-κB decoy oligo A, directed towards atopic dermatitis

In Japan, 2,8 million people suffer from atopic dermatitis, 10 million in the US.

AnGes MG press release, April 17, 2013

Shionogi and AnGes MG start phase I of NF-κB decoy oligo A, directed towards atopic dermatitis
Scroll to top